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Abstract
Ovarian cancer is the most common cause of death from gynecological cancer. Understanding the biology of this disease,
particularly how tumor-associated lymphocytes and fibroblasts contribute to the progression and metastasis of the tumor,
has been impeded by the lack of a suitable tumor xenograft model. We report a simple and reproducible system in which
the tumor and tumor stroma are successfully engrafted into NOD-scid IL2Rc
null (NSG) mice. This is achieved by injecting
tumor cell aggregates derived from fresh ovarian tumor biopsy tissues (including tumor cells, and tumor-associated
lymphocytes and fibroblasts) i.p. into NSG mice. Tumor progression in these mice closely parallels many of the events that
are observed in ovarian cancer patients. Tumors establish in the omentum, ovaries, liver, spleen, uterus, and pancreas.
Tumor growth is initially very slow and progressive within the peritoneal cavity with an ultimate development of tumor
ascites, spontaneous metastasis to the lung, increasing serum and ascites levels of CA125, and the retention of tumor-
associated human fibroblasts and lymphocytes that remain functional and responsive to cytokines for prolonged periods.
With this model one will be able to determine how fibroblasts and lymphocytes within the tumor microenvironment may
contribute to tumor growth and metastasis, and will make it possible to evaluate the efficacy of therapies that are designed
to target these cells in the tumor stroma.
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Introduction
Both normal and neoplastic human tissues have been
successfully engrafted into T cell and B cell-deficient prkdc
scid (scid)
mice. The first successful engraftment of human cells into these
C.B-17 scid mice was reported over 20 years ago [1]. The use of
human tissue xenografts in these immunodeficient mice has since
led to insights into the biology of human cancer, autoimmunity
and infectious diseases [2]. The potential of using several different
human tumor xenograft models to study and evaluate anti-cancer
therapies along with the models’ limitations and pitfalls has been
reviewed [3]. One of the greatest impediments of the earlier
xenograft models was the host-versus-graft (HVG) response that
was observed following the implantation of human tissues. While
scid mice lacked functional B and T cells, these mice had an intact
innate immune response that was responsible for the complex
cellular and molecular HVG response. The intensity of this HVG
response varied considerably from mouse to mouse and with the
histological type of tumor used for engraftment [3]. Enhanced
levels of human tissue engraftment have depended primarily upon
genetic modifications of immunodeficient host mice [2]. A major
breakthrough was the generation of immunodeficient mice that
are homozygous for targeted mutations at the interleukin-2
receptor c chain locus [2]. These mice are severely impaired in
the development and function of T cells, B cells and NK cells [2].
One example of this new type of immunodeficient mouse strain is
the NOD.Cg-Prkdc
scidIL-2rg
tm1Wjl, abbreviated NSG. Immunodefi-
cient mice lacking the IL-2 receptor c chain have been found to
support the prolonged engraftment of human hematopoietic cells
and peripheral blood mononuclear cells [2] better than previous
immunodeficient mouse strains.
A xenograft model in which human tumors and autologous
tumor-associated T and B cells could be co-engrafted and their
interactions studied in vivo would provide an opportunity to
determine how human immunocompetent cells and tumor cells
influence each other. The findings could potentially be used to
evaluate immunotherapeutic approaches to cancer. Further, in
view of the increasing awareness that nonmalignant stromal cells
including fibroblasts, epithelial cells and other leukocytes interact
with and have an impact upon tumor growth and metastases [4],
the development and use of models in which the tumor
microenvironment is maintained in the xenograft is also critical
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implanting non-disrupted pieces of human tumors subcutaneously
into NSG mice, xenografts were established in which the tissue
architecture, including tumor-associated leukocytes, stromal fibro-
blasts and tumor cells was preserved and maintained for prolonged
periods [5]. This model proved useful in demonstrating the ability
of exogenous IL-12 delivered by biodegradable microspheres to
activate quiescent memory T cells within the tumor microenvi-
ronment [5]. However, because these tumor xenografts were not
established orthotopically, and only limited evidence of tumor
spreading was observed, the model did not accurately reflect the
patterns of growth and metastasis that are observed in cancer
patients, and was therefore of limited potential value in identifying
factors that contribute to tumor metastasis or for assessing the
efficacy of immunotherapeutic protocols.
A tumor xenograft model has been developed and is reported
here in which human epithelial ovarian tumor xenografts are
established orthotopically, and the pattern of tumor growth and
metastasis reflects that which is observed in ovarian cancer
patients. Tumor-associated T and B lymphocytes and fibroblasts
co-engraft within tumor nodules and the T cells remain functional
and responsive to exogenously administered cytokine. CA125 is
present in the sera and ascites of CA125+ tumor-bearing mice and
provides an opportunity to monitor the presence and progress of
tumor xenografts periodically. It is expected that this model will
make it possible to study the ability of human tumor-associated
leukocytes and tumor stroma to modulate in situ tumor
progression. Moreover, the model provides the potential to
evaluate the efficacy of single, as well as combination, therapeutic
approaches to ovarian cancer.
Results
Human ovarian epithelial tumors engraft orthotopically
in the ovary and other organ sites following the
intraperitoneal (i.p.) injection of tumor-derived cell
aggregates into NSG mice
It was established previously that the subcutaneous implantation
of solid pieces of fresh human tumor tissues into NSG mice
resulted in the establishment of tumor microenvironments [5].
The advantages of this approach over previous methods were that
the resultant xenografts maintained their original architecture,
including tumor-associated leukocytes, stromal fibroblast and
tumor cells, and the xenografts survived for prolonged periods
without HVG interference or infiltration of host cells. A major
limitation of this earlier xenograft model was that it failed to reflect
the patterns of tumor growth and spreading that are observed in
cancer patients, and some tumors failed to engraft or resulted in
xenografts with large areas of necrosis due to an inadequate
vascularization of the solid pieces of tumors.
We report here a method of engraftment, in which ovarian
tumors can be successfully established as xenografts orthotopically
in the ovary and other organ sites of recipient mice. The tumor
growth reflects the pattern and progression observed in ovarian
cancer patients. This has been accomplished by injecting a
suspension of cell aggregates (that is derived from a mild disruption
of solid ovarian tumors) i.p. into NSG mice (see Methods section).
To insure successful tumor engraftment, the tumor biopsy tissues
must consist of areas of viable tumor cells that include tumor-
associated lymphocytes, and fibroblasts as shown in Fig. 1. The
tumor-derived-cell suspensions resulting from the disruption of the
fresh solid tumor tissues contain small (200–300 mm diameter)
aggregates of cells that include CD45+ leukocytes, cytokeratin
positive tumor cells, CD3+ T cells and trichrome positive collagen
which is produced by fibroblasts (Fig. 2A–E). Cell aggregates
derived from ovarian tumors obtained from five different patients
(Experiment1–5) wereinjected i.p.into NSGmiceand therecipient
mice sacrificed at the times indicated in Table 1. While histological
evidence of the attachment and growth of the tumor cell aggregates
were observed on the omentum as early as 8 days post i.p.
inoculation (data not shown) gross and histological evidence of
tumor and tumor stroma within different organ sites (discussed
below) was not established until 80 to 177 days post inoculation
(Table 1). None of the mice showed any obvious clinical signs of
tumor development during the first 10 weeks of observation
following the tumor inoculation. Death was often the first sign of
tumor engraftment. One mouse from each experiment died without
evaluation, and was not included in the final analysis.
Nodules detected grossly within the peritoneal cavity of mice
injected with tumor-derived cell aggregates were confirmed
histologically to be tumors (Fig. 3Aa and 3Ab). The tumor
nodules varied in diameter from 2 mm to 10 mm and were most
frequently observed within or near the area of the omentum, i.e.
adjacent to the stomach, spleen and pancreas. In some mice
tumors were observed grossly on the surface of the spleen and
liver. To determine whether the tumors had spread to other organ
Figure 1. Histology of the original tumor. A section of a papillary
serous adenocarcinoma of the ovary stained with hemotoxylin and
eosin (H&E). Shown in A 1006 magnification and in B 4006
magnification clusters of tumor cells (T) that show lymphocytic
infiltration (L), along with fibrous connective tissue (F).
doi:10.1371/journal.pone.0024420.g001
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taken, fixed and stained. Fig. 3Ac–3Ag reveal the presence of
tumor in the ovary, periovarian fat, pancreas, uterus, spleen and
liver from a mouse sacrificed 140 days after the injection of tumor-
derived cell aggreages (Experiment #4).
The frequency of tumors observed histologically in different
organ sites varied from tumor to tumor and from mouse to mouse
for each tumor-derived cell aggregate implanted. In a typical
example of the organ distribution in 15 mice, 116 days after the
i.p. injection of cell aggregates derived from solid ovarian tumors
(Experiment 5A, Table 1), histological evidence of tumor was
detected in the ovary of 10 mice, the spleen of 10 mice, the liver of
8 mice, and the uterus of 2 mice. It is considered likely that this
organ site involvement is an underestimate of the actual frequency
of tumors in the different organs, because only a small area of each
organ was examined histologically.
Human CD45+, CD3+,C D 2 0 +, CD138+ Leukocytes,
Fibroblasts and Proliferating Tumor Cells are Present in
the Microenvironment of Tumor Xenografts
Sections of tumor nodules removed from the peritoneal cavity
and stained with hemotoxylin and eosin revealed areas in which
lymphocytes (see arrow) were present in juxtaposition with tumor
cells (see arrowhead) (Fig. 3Ba). Immunohistochemical staining of
this tissue established that the tumor-associated lymphocytes were
human CD45+ and included CD3+ T cells, CD20+ B cells, and
CD138+ plasma cells (Fig. 3Bb–Be). Tumor cells stained positively
for HLA Class I (Fig. 3Bf), and included actively dividing Ki67
positive cells (Fig. 3Bg).
A trichromestain of thetumor nodules showedthat inaddition to
the inflammatory cells, fibroblasts were present within the
microenvironment of the tumor xenografts (see arrow) (Fig. 3Bh).
The fibroblasts stained positively for HLA Class I (data not shown).
We conclude that the histological architecture and cellular
composition including the tumor cells, inflammatory leukocytes
and fibroblasts of the original tumor tissue are maintained for
prolonged periods (up to 177 days post-engraftment) in the tumor
xenograft, and that tumor cells continue to proliferate within the
tumor nodules present in the peritoneal cavity.
Tumor Ascites Development in NSG Mice Inoculated with
Ovarian Tumor-Derived Cell Aggregates
Ovarian cancer patients typically develop a tumor ascites in the
later stages of their disease [6,7]. To determine whether tumor
ascites develop in the tumor xenograft model, NSG mice were
monitored for prolonged periods following the i.p. inoculation of
tumor-derived cell aggregates. Distended abdomens were observed
Figure 2. Presence of tumor, T cells and fibroblasts in tumor
cell aggregates. Histology and immunohistochemistry of tumor-
derived cell aggregates derived by mild disruption of a primary ovarian
tumor. H&E staining show clusters of cells of different sizes (A)
Immunohistochemical staining for human CD45 (B) and CD3 (C) shows
evidence of human leukocytes and T cells, i.e. dark brown stained cells.
Trichrome staining (D) reveals the presence of collagen which is
produced by fibroblasts and stains aquamarine. Tumor cells stain dark
brown with immunohistochemical stain for cytokeratin (E). All figures
are at 4006magnification.
doi:10.1371/journal.pone.0024420.g002
Table 1. Frequency of Tumor Development Following i.p. Injection of Tumor Cell Aggregates Derived from Ovarian Cancer Patient
Solid Tumors.
Experiment #
a Tumor Type # Mice Implanted
b Days Post Inoculation Evidence of Tumor
c
1 Papillary Serous Carcinoma 10 80 8/9
2 Papillary Serous Carcinoma 10 82 9/9
3 Papillary Serous Carcinoma 10 115 9/9
4 Papillary Serous Carcinoma 10 140 8/9
5A Adenocarcinoma 15 116 13/15
5B Adenocarcinoma 5 177 4/4
aEach experiment was conducted with tumor tissue derived from a different ovarian cancer patient. In experiment 5A and B the cell aggregates was generated from the
same tumor.
bMice were injected i.p. with tumor-derived cell aggregates obtained from five different ovarian cancer patients, that is generated as indicated in Materials and Methods
section.
cEvidence of tumor was established by the presence of grossly detected tumor nodules in the peritoneal cavity, histological evidence of tumor in the organs or both. In
each experiment, #1–4, one of the 10 mice died without evaluation. In experiment #5 one of the mice was sacrificed at day 85 post inoculation without any evidence
of gross tumor. In experiment 5B – one of the mice died without evaluation.
doi:10.1371/journal.pone.0024420.t001
Growth and Metastasis of Ovarian Cancer Xenografts
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24420in mice by 14 weeks after tumor injection suggesting the presence of
ascites. Paracentesis confirmed the presence of ascites fluid in the
peritoneal cavity of the mice. To determine whether viable tumor
cells were present within the ascites fluid, the ascites fluids from
tumor bearing mice (generated by the i.p. inoculation of ovarian
tumor-derived cell aggregates from three different ovarian cancer
patients) were injected i.p. into naı ¨ve NSG mice. Eighty-seven to 94
days post-inoculation mice had histological evidence of tumor
development in the ovary, uterus, liver, spleen and lung (data not
shown). Most of these secondary recipients had also developed
ascites by this time. These results establish both the presence of
viable tumor cells in the ascites fluid of the original tumor bearing
mice, and the ability to sub-passage the tumor and thereby expand
the number of mice with tumor xenografts. Tumors have now been
successfully sub-passaged three times. After the third passage the
tumor xenografts appear to be largely devoid of human tumor
associated fibroblasts and tumor associated lymphocytes.
Presence of CA125 in the Sera and Ascites of Ovarian
Tumor Bearing NSG Mice
CA125 is a high molecular weight glycoprotein that is elevated
in the serum of approximately 90% of patients with advanced
epithelial ovarian cancer [8,9], and is used to monitor tumor
progression and response to chemotherapy in ovarian cancer
patients [8]. Because the only clinical sign of tumor development
in the mice was tumor ascites that occurred very late, it was of
interest to determine whether CA125 levels could be detected in
the NSG mice engrafted with ovarian tumor-derived cell
aggregates, and to establish whether this marker could be utilized
to periodically monitor the presence and progression of the human
tumors in mice following the tumor inoculation. The cell
aggregates were derived from solid tumors of three different
ovarian cancer patients with elevated serum levels (.500 u/ml) of
CA125. Each of the three tumor-derived cell aggregates was
injected i.p. into 10 NSG mice and the CA125 levels in the serum
and ascites were assayed at different times after tumor inoculation.
By 80 days post tumor inoculation, CA125 was present in the
ascites and sera of all mice inoculated with tumors derived from
the three different patients. In one of the three groups of mice the
animals were bled periodically and the serum levels of CA125
determined. The CA125 in the serum increased with time
reaching a level of greater than 500 units/ml 100 days post
tumor-derived cell aggregate inoculation. The amount of CA125
in the ascites varied considerably from tumor to tumor reaching
levels of 400–5800 units/ml 85–116 days post tumor-derived cell
aggregate inoculation. The ability to detect CA125 in the serum
and ascites of tumor xenograft bearing mice is reflective of yet
another event that is observed in ovarian cancer patients, and is
significant as it provides a way to periodically monitor the presence
and progression of the tumor, and ultimately to assess the
therapeutic efficacy of different treatment protocols.
Metastatic Spread of Ovarian Tumor Xenografts from the
Abdominal Cavity into the Pleural Space
The intra-abdominal spreading that we observed following the
i.p. inoculation of ovarian tumor-derived cell aggregates into NSG
Figure 3. Tumor and stroma in multiple organs in NSG mice following injection of tumor aggregates. H&E staining shows evidence of
tumor (see arrows) in peritoneal nodule from omentum (Aa and Ab), ovary and periovarian fat (Ac), pancreas (Ad), uterus (Ae), spleen (Af), and liver
(Ag). These tumors resulted from the i.p. injection of tumor-derived cell aggregates derived from a papillary serous carcinoma of the ovary. Mice were
sacrificed 140 days post inoculation. Lymphocytes (arrow) were observed in juxtaposition with tumor cell (arrowhead) (Ba). Immunohistochemical
staining (B) shows the presence of human CD45+ leukocytes (Bb), CD3+ T cells (Bc), CD20+ B cells (Bd), CD138+ plasma cells (Be), and HLA+ tumor
nodule adjacent to the ovary (Bf). Proliferation of tumor cells is shown by positive stain with KI67 (Bg), and evidence of stromal fibroblasts illustrated
by trichrome staining of collagen see arrows (Bh). Arrow head shows tumor cells. All sections in A are at 1006magnification and in B the sections are
at 4006magnification.
doi:10.1371/journal.pone.0024420.g003
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what is seen in Stage IIIc ovarian cancer patients [7]. At this stage
the disease may involve the omentum, bowel mesentery,
abdominal peritoneal surfaces, serosal surface of the bowel and
the diaphragm. Mice that had developed tumor ascites by 16
weeks after the i.p. injection of tumor-derived cell aggregates, had
gross evidence of tumors on the serosal surfaces of the bowel and
omentum and were carefully examined for diaphragmatic tumor
implants. Gross evidence of possible tumor growth was observed
on the diaphragm of 12 of 15 mice inoculated with the tumor-
derived cell aggregates. Histological analysis confirmed the
presence of tumor growth on the diaphragm (Fig. 4A).
Stage IV disease patients present with evidence of extra-
abdominal spreading of the tumor and this may involve the pleural
space with metastasis into the lung parenchyma [7]. While no
gross evidence of tumor metastasis in mice was observed by 16
weeks post tumor-derived cell aggregate inoculation, histological
analysis of the lungs established that micro-metastasis of the tumor
from the peritoneal cavity had occurred in 4 of 15 mice. Small foci
of tumors observed in the lung (Fig. 4B,C) stained positively for
HLA Class I (Fig. 4D). The number of mice with lung metastasis is
likely an underestimate as only a small portion of the lung was
examined histologically.
Our collective findings indicate that the slow and progressive
pattern of tumor growth and metastasis of ovarian tumors in NSG
mice following the i.p. inoculation of fresh human ovarian tumor-
derived cell aggregates closely reflects that seen in patients who
develop into Stages IIIc and IV of disease which accounts for over
70% of the ovarian cancer patients seen in the clinic [7].
Human T cells present in xenografts produce IFN-c upon
activation with exogenous IL-12 and plasma cells
constitutively produce immunoglobulin (Ig)
Lymphocytes including effector memory CD4+ T cells [10],
NY-ESO-1 tumor specific CD8+ T cells [11], CD4+ and CD8+
regulatory T cells [12–14], and TH17 cells [15] have been found
within ovarian tumor microenvironments. These and other tumor
infiltrating leukocytes have been shown to be associated with both
the enhancement and inhibition of tumor progression [16]. It was
of interest and relevant to the potential utility of our humanized
mouse model to establish whether the tumor-associated lympho-
cytes that were found in the tumor xenografts remained viable and
functional. Having established by immunohistochemistry the
presence of human CD45+ leukocytes CD3+ T cells, CD20+ B
cells and CD138+ plasma cells in the tumor microenvironment of
xenografts established following the i.p. injection of tumor-derived
cell aggregates (Fig. 3B), the viability and the capacity of these cells
to respond to exogenous cytokine stimulation in vivo were
investigated.
We have previously established that T cells in the tumor
microenvironment have an attenuated TCR driven activation
signal, but remain viable and respond to stimulation with IL-12 by
producing IFN-c [17,18]. If the T cells present in the tumor
xenografts remained viable we predicted that there would be a
significant increase of IFN-c in the sera of tumor bearing mice
following the treatment of the mice with IL-12 [19]. Tumor
bearing mice (21 days post tumor inoculation) were injected i.p.
with either human IL-12 loaded liposomes (50 mg of IL-12 per
mouse) or control (empty) liposomes, and their sera were assayed 5
days later for the presence of human IFN-c. While the level of
IFN-c in the sera of the IL-12 treated mice varied from mouse to
mouse, 9 out of 10 of these mice showed significantly elevated
levels of IFN-c (233–5392 mg/ml) (Table 2). All 5 of the tumor
bearing mice treated with control liposomes had lower serum
levels of IFN-c ranging from 32–88 pg/ml. These results suggest
that the human tumor-associated T lymphocytes, and possibly NK
cells, present in the tumor bearing mice are both viable and
Figure 4. Spontaneous metastasis of tumor xenograft into the
lung. H&E staining (1006magnification) reveals the presence of tumor
in the diaphragm (A), and in the lung 1006magnification (B) and 4006
magnification (C). The immunohistochemical staining of the tumor in
the lung for HLA Class I (D) establishes that these tumors are of human
origin. The sections were made from the tissues of a mouse 16 weeks
after the i.p. injection of a suspension of tumor=derived cell
aggregates.
doi:10.1371/journal.pone.0024420.g004
Table 2. Evidence of Viability and Function of T Cells and
Plasma Cells in Tumor Bearing Mice.
Treatment of Mice
a IFN-c (pg/ml)
b Human Ig (mg/ml)
c
Empty Liposome 32.0 500
Empty Liposome 87.9 550
Empty Liposome 38.2 38
Empty Liposome 32.0 ,25
Empty Liposome 32.0 ,25
IL-12 Liposome 66.1 458
IL-12 Liposome 469.6 738
IL-12 Liposome 416.9 435
IL-12 Liposome 842.1 816
IL-12 Liposome 1379.1 456
IL-12 Liposome 5392.4 Died
IL-12 Liposome 357.9 1123
IL-12 Liposome 233.7 1361
IL-12 Liposome 376.5 868
IL-12 Liposome 3191.8 743
aNSG mice injected i.p. with control empty liposomes or liposomes loaded with
IL-12. The dose of IL-12 was 50 mg/mouse. All mice were treated 21 days after
i.p. injection of the tumor-derived cell aggregates.
bMice were bled 5 days after treatment, and the serum levels of IFN-c
determined by ELISA. Each value represents the serum level from a single
mouse.
cMice were bled 78 days after treatment and the serum levels of human
immunoglobulin determined by ELISA. Each value represents the serum level
from a single mouse.
doi:10.1371/journal.pone.0024420.t002
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in a significant decrease in tumor progression compared to control
mice. Future studies are planned to assess the effect of multiple
treatments of the mice with IL-12 either alone or in combination
with chemotherapy.
The viability and function of B cells and plasma cells in the
tumor bearing mice were addressed by assaying the sera for the
presence of human Ig. We consistently observed high levels of
human Ig in the sera of tumor bearing mice (Table 2). In one
representative experiment, elevated levels of Ig were observed in
mice 78 days post treatment in both IL-12 treated and control
mice, and no consistent enhancement of the serum Ig levels has yet
been seen in response to IL-12.
The presence of both functional tumor-associated T and B cells
in the tumor xenograft bearing mice for .100 days provides an
opportunity to investigate the possible role that these lymphocytes
(and the biologically active factors they produce, i.e. cytokines and
antibodies) play in the survival and metastasis of the tumor, and to
determine whether it is possible to manipulate these lymphocytes
so that they mount an effective anti-tumor response in situ.
Discussion
Since the first report on the successful engraftment of human cells
in C.B-17-scid mice [1], several thousand papers have been
published on the use of these and other immunodeficient mice to
engraft human malignant and non-malignant tissues in studies of
human cancer, hematopoiesis, adaptive and innate immunity,
infectious diseases, autoimmunity and regenerative medicine [2].
Mouse models have been used to study cancer cell growth and to
preclinically evaluate the therapeutic efficacy of immune based and
non-immune based treatment strategies for cancer. Limitations of
these earlier models included a significant innate immune response
of the recipient mice that limited the duration of the graft and made
it difficult to interpret results of therapeutic efficacy studies. These
xenograft models failed to recapitulate the sites and patterns of
tumor growth and in most of the models co-engraftment of stromal
cells with the tumor was not established [3].
We report here a humanized model that more closely parallels
the patterns of tumor progression that are observed in ovarian
cancer patients than does any other previously described model.
Our model captures several important features of human ovarian
cancer not seen in previous models. The intra-abdominal
spreading along with the development of ascites is strikingly
similar to what is observed in patients. The co-engraftment of
tumor-associated fibroblasts and T and B lymphocytes that remain
viable and functional for prolonged periods provides an opportu-
nity to investigate the possible contribution of these non-malignant
cells, and the biologically active factors they produce, to the
growth and spread of the tumor cells.
The orthotopic engraftment and dissemination of the tumor and
co-engraftment of tumor-associated immunocompetent cells with
tumor stroma in this new humanized mouse model make it
possible to study in vivo the interaction between lymphocytes and
the tumor, lymphocytes and tumor-associated fibroblasts and
fibroblasts and the tumor. It has previously been established that
tumor stroma is critical for preventing or permitting the
immunological destruction of cancer cells [20]. This work was
later confirmed [21] and then extended showing that the tumor
stroma leads to a T cell mediated eradication of established tumor
[22]. Orimo et al. showed that fibroblasts derived from human
invasive breast carcinomas significantly enhanced tumor growth in
xenograft models [23]. Tumor-associated fibroblasts have been
shown by others to enhance or suppress T cell function [24–26]
and subsets of tumor-associated T cells are known to interact with
tumor cells and reciprocally modulate each other [27]. Whether
fibroblast or leukocytes present within human tumor microenvi-
ronments enhance and/or suppress tumors remains to be
established [28,29]. By depleting, functionally inhibiting or
activating specific subsets of cells within the tumor-derived cell
aggregates prior to inoculation in NSG mice the effect upon the
engraftment and subsequent intra-abdominal spreading and
metastasis into the extra-abdominal pleural space can be
determined, thereby establishing which cells in the tumor
microenvironment contribute to tumor arrest or enhancement of
tumor progression.
Ovarian cancer is most often asymptomatic in its early stages as
most patients have widespread disease at the time of diagnosis
[30]. New insights into the pathogenesis and origin of serous
ovarian cancer may ultimately lead to an earlier diagnosis of this
disease. Increasing evidence has indicated that most or all high-
grade serous ovarian carcinomas originate in fallopian tubes
[31,32]. Elevated serum levels of CA125 (a tumor marker protein)
are found in .90% of patients with advanced stage ovarian
cancer, but comparatively few patients with Stage I disease are
CA125 positive. Similarly mice inoculated i.p. with tumor-derived
cell aggregates show no clinical evidence of tumors for at least 80
days when elevated CA125 levels in the sera were first detected.
The serum CA125 level then increased rapidly reaching levels
exceeding 500 units/ml by day 100 post inoculation. At this time
and beyond the mice exhibited a pathology consistent with Stage
IIIc and IV of ovarian cancer, i.e. evidence of intra-abdominal
spread into multiple organ sites, diaphragmatic implants, devel-
opment of tumor ascites and extra-abdominal spread into the
pleural space with metastases to the lung [7].
Thus, while CA125 levels are a reliable indicator of the presence
and expansion of ovarian tumors in patients and in our humanized
mouse model, it is not suitable for early tumor detection in either
patients or in mice inoculated with the tumor-derived cell
aggregates. However, serum levels of CA125 are currently used
effectively to monitor ovarian cancer patients’ response to
chemotherapy and surgery [8]. This biomarker has also been
used as a prognostic indicator for ovarian cancer patients. We
expect that serum CA125 levels will also be a very useful
quantifiable marker to monitor periodically and compare in vivo
therapeutic effects in our humanized mouse model.
The enhanced ability of small aggregates of tumor and non-
malignant tumor cells to establish, grow and spread within the
peritoneal cavity (compared to solid non-disrupted pieces of tumor
tissue) may depend upon the ability of small cell clusters to survive
initially until a sufficient vascular supply is established to permit
tumor expansion. The success of the engraftment of tumor-derived
cell aggregates may also depend in part upon the contribution of
biologically active factors produced by the non-malignant cells in
the cell aggregates that produce tumor growth factors and
stimulants to angiogenesis. Tumor masses most often occur first
in the cranial areas of the peritoneal cavity near and within the
omentum. The position of the tumor nodules as well as the
enhanced growth of the cell aggregates and slow progression of the
tumors to other organs may result from the initial attachment of
the tumor cell aggregates to highly vascularized areas within the
omentum called milky spots. These discrete areas were first
recognized by Ranvier [33] and have been shown to be sites where
tumors attach preferentially and proliferate following the i.p.
injection of several different murine tumor cell lines and a human
ovarian tumor cell line into mice [34,35]. Others have suggested
that the intraperitoneal spreading of the tumor in ovarian cancer
patients may occur by the attachment of tumor cells to the milky
Growth and Metastasis of Ovarian Cancer Xenografts
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therapeutic approach in these patients [37–39] in an attempt to
prevent further spreading of the tumor.
The results presented here suggest that our humanized NSG
mouse ovarian transplant model has the potential to serve as a
useful preclinical tool with which to test the efficacy of
chemotherapeutic strategies, immunotherapeutic strategies or
combinations of both. One of the attractions of this model is that
it makes it possible to test strategies that target tumor-associated T
cells and thereby initiate an anti-tumor response. One possible use
of the model would be to test the ability of a cytokine such as IL-12
to initiate systemic anti-tumor responses. While the single
treatment of tumor bearing mice 21 days post tumor inoculation
did not result in a significant inhibition of tumor progression,
future studies will assess the effect of multiple treatments with IL-
12 or IL-12 in combination with other cytokines and chemother-
apy. This type of an in situ strategy of cancer vaccination has
already been demonstrated to be efficacious in several mouse
tumor models [40–42].
The humanized mouse model described here has focused solely
upon the engraftment of epithelial ovarian cancer tissues. Whether
or not this approach could be used effectively to engraft and study
other tumors that originate in the peritoneal cavity is currently
being investigated. Other orthotopic xenograft models of intra-
peritoneal tumors have been reported [43,44], but none have
included the co-engraftment of the non-malignant tumor stroma
or have recapitulated the patterns of growth and metastasis seen in
patients.
A key factor in the success of the engraftment and long-term
survival of human tumor xenografts has been the use of the NSG
mice [5]. These mice have also been used most effectively to study
the engraftment, growth and spontaneous metastasis of human
tumor stem cells and have been shown to be significantly more
efficient in the detection of tumorigenic cells [45,46]. These
severely immunodeficient mice will continue to be critical in
establishing xenografts that recapitulate the growth and spreading
patterns of tumors observed in patients and have the potential to
serve as reliable preclinical models to evaluate cancer therapies.
Materials and Methods
Ethics Statement
Tumor tissues were obtained with an IRB-approved protocol
covered under Human Subject Assurance Number 00008824
assigned through the UB Health Sciences Institutional Review
Board accredited by the Association for the Accreditation of
Human Research Protection Programs. All animal work was
conducted with an Institutional Animal Care and Use Committee
(IACUC) approval covered under Animal Welfare Assurance
Number A3354-01 accredited through the Association for
Assessment and Accreditation of Laboratory Animal Care.
Tumor samples
The Roswell Park Cancer Institute Tissue Procurement Facility
provided the human primary and metastatic ovarian solid tumor
tissue and ovarian ascites fluid. All samples were provided under
sterile conditions using Institute Review Board approved proto-
cols.
Processing of tumor
Tumor tissue was mechanically disrupted using a Teflon
policeman to generate clusters or aggregates of cells that passed
through a size 50 stainless steel wire mesh. The resulting tumor-
derived cell aggregates were washed once in RPMI 1640 and
resuspended in PBS, pH 7.2. Aggregates of cells in size from
approximately 200–300 mm in diameter and included tumor cells,
fibroblasts, endothelial cells and lymphocytes.
Preparation and loading of IL-12 liposomes
Large multilamellar liposomes were prepared by rehydrating
the lipid film of appropriate molar ratios of distearoyl phospha-
tidylcholine (DSPC), dimyristoyl phosphatidylglycerol (DMPG)
and cholesterol (CHOL) (DSPC:DMPG:CHOL; 80:20:25) with
phosphate buffer containing recombinant human IL-12 at 45uC.
The spontaneous loading of a large complex molecule such as IL-
12 is accomplished by a mild denaturation of IL-12 to partially
and reversibly unfold the protein to expose hydrophobic domains
resulting in the intercalation of the cytokine within or between the
lipid bilayers of the liposomes [19]. This technique called triggered
loading results in an optimal loading of the IL-12 which retains its
biological activity. After rehydration lipids are gently swirled and
incubated at 45u for 10 minutes, then 15 minutes at 4uC for 3
cycles as described in Simpson-Abelson et al. [19].
Tumor implantation into mice
Suspensions of tumor-derived cell aggregates were injected i.p.
into NSG mice. All NSG mice raised in a high barrier research
colony at The Jackson Laboratory, were housed in specific
pathogen-free conditions at SUNY at Buffalo. Each mouse
received between 100 to 300 mg of the cell aggregates in a
volume of 1.0 ml. All animal experiments were approved by the
Institute Animal Care and Use Committee at SUNY at Buffalo.
Treatment of mice with recombinant human IL-12
Wyeth Laboratory provided the recombinant human IL-12 that
was incorporated into liposomes as described above. Mice bearing
the human ovarian tumor xenograft were randomly divided into
control and treatment groups. Mice were treated with a) empty
liposomes, b) IL-12 containing liposomes (50 mg/mouse) – once or
multiple times or c) left untreated. The dose of IL-12 was
determined based upon the calculated loading efficiency for each
liposome preparation. All of the cytokine was associated with the
liposome as the free IL-12 was removed from the liposome
preparations prior to injection.
Mouse serum or plasma collection
Blood samples were collected via a retro-orbital sinus bleed.
Clotted blood was centrifuged at 10006g for 20 minutes and sera
harvested and stored at 220uC until use.
Human IFN-c ELISA
A sandwich ELISA for the detection of human IFN-c in mouse
serum was performed as previously described [24]. Briefly 96 well
plates were coated using a monoclonal antibody to IFN-c (M-700-
a; Endogen). Dilutions of mouse sera were added to the plate with
a biotinylated monoclonal anti-human IFN-c (M-701-B; Endo-
gen). Positive binding was detected using strepavidin-conjugated
HRP (Sigma–Aldrich), peroxide and 3,39,5,59-tetramethylbenzi-
dine (SureBlue from KPL). Results were measured on a Bio-Tek
Instruments automated microplate reader at OD450–540 and
analyzed by comparison with a recombinant IFN-c standard
using SigmaPlot software.
Human IgG Immunoassay
The ELISA for the detection of human Ig (huIg) in mouse
serum was reported previously [5]. Briefly, 96 well plates were
coated using rabbit anti-human Ig (Accurate Chemical, Westbury,
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Bound huIg was detected using rabbit anti-human Ig-HRP, and a
tetramethylbenzidene (TMB) peroxidase substrate (SureBlue from
KPL, Gaithersburg, MD). Results were measured on a BioTek
microplate reader at OD450–540 and analyzed with a human Ig
standard (from Accurate Chemical, Westbury, NY) using Sigma
Plot software.
CA125 Immunoassay
Levels of CA 125 were determined by analysis with the Bayer
Immuno ITM CA-125 II assay (Bayer Corp, Pittsburgh, PA).
Histology and immunohistochemistry
H&E staining was performed by the SUNY at Buffalo Histology
Service Laboratory where fresh surgical sections of the original
tumor, xenografts and mouse tissues were fixed in 10% neutral-
buffered formalin and processed for paraffin embedding. Anti-
human specific antibodies to the following markers were used for
immunohistochemical staining of the xenografts and mouse
tissues: anti-CD3 (Dako), anti huHLA-A Class I (Santa Cruz),
anti-huCD45 (R&D Systems), anti-hu 138 (Dako) and anti-hu
CD20 (ab Cam). Staining was performed as previously re-
ported [5].
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